Nicotinamide for OPA1 Dominant Optic Atrophy

We are studying whether nicotinamide (vitamin B3) is safe and effective for people with OPA1 Dominant Optic Atrophy. The trial will assess its impact on vision and overall quality of life.

>2 years Confirmation phase (III)No Placebo Cost Reimbursement Standard Medicines OralNeurologyOphthalmology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Nicobion

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Nicotinamide

Nicotinamide is a form of vitamin B3 that supports body energy processes and helps maintain healthy skin.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Freederm

Freederm Treatment

Nicotinamid Axicur

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Centre Hospitalier Universitaire D Angers

Biochemistry and molecular biology

Angers, France

Sponsor: Centre Hospitalier Universitaire D Angers

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.